

David P Nicolau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4381899/publications.pdf>

Version: 2024-02-01

387
papers

7,917
citations

66343

42
h-index

110387

64
g-index

391
all docs

391
docs citations

391
times ranked

5840
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 443-447.	3.0	12
2	Intrapulmonary Pharmacokinetic Modeling and Simulation of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients With Pneumonia and Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 670-680.	2.0	10
3	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. <i>Hospital Pharmacy</i> , 2022, 57, 496-503.	1.0	2
4	<i>In Vitro</i> Time-Kill Studies of Trimethoprim/Sulfamethoxazole against <i>Stenotrophomonas maltophilia</i> versus <i>Escherichia coli</i> Using Cation-Adjusted Mueller-Hinton Broth and ISO-Sensitest Broth. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, aac0216721.	3.2	6
5	Pharmacokinetics of Cefazolin in Patients With Obesity Undergoing Surgery Requiring Cardiopulmonary Bypass. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2942-2947.	1.3	2
6	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1052-1060.	3.0	12
7	Pharmacokinetic/Pharmacodynamic Optimization of Hospital-Acquired and Ventilator-Associated Pneumonia: Challenges and Strategies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, , .	2.1	0
8	<i>In vivo</i> efficacy of WCK 6777 (ertapenem/zidebactam) against carbapenemase-producing <i>Klebsiella pneumoniae</i> in the neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1931-1937.	3.0	4
9	Omadacycline pharmacokinetics and soft-tissue penetration in diabetic patients with wound infections and healthy volunteers using <i>in vivo</i> microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	5
10	Murine Model for Measuring Effects of Humanized-Dosing of Antibiotics on the Gut Microbiome. <i>Frontiers in Microbiology</i> , 2022, 13, 813849.	3.5	1
11	Carbapenemase-producing <i>Pseudomonas aeruginosa</i> –an emerging challenge. <i>Emerging Microbes and Infections</i> , 2022, 11, 811-814.	6.5	68
12	Comparison of Zinc Concentrations in the Broth of Commercial Automated Susceptibility Testing Devices (Vitek 2, MicroScan, BD Phoenix, and Sensititre). <i>Microbiology Spectrum</i> , 2022, 10, e0005222.	3.0	2
13	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab617.	0.9	3
14	Evaluation of high-concentration EDTA-modified carbapenemase inactivation method (eCIM) for SPM-producing <i>Pseudomonas aeruginosa</i> . <i>Archives of Microbiology</i> , 2022, 204, 55.	2.2	0
15	Assessment of sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against <i>Acinetobacter baumannii</i> using <i>in vitro</i> chemostat and <i>in vivo</i> murine infection models. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac047.	2.1	6
16	OUP accepted manuscript. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, , .	3.0	0
17	<i>In vitro</i> potency of amikacin against carbapenem-resistant <i>Pseudomonas aeruginosa</i> : A target for nebulization strategy?. <i>Brazilian Journal of Infectious Diseases</i> , 2022, 26, 102355.	0.6	0
18	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>International Journal of Antimicrobial Agents</i> , 2022, 60, 106603.	2.5	7

#	ARTICLE	IF	CITATIONS
19	Ertapenem Concentrations in Obese Patients Undergoing Surgery. <i>Surgical Infections</i> , 2022, 23, 545-549.	1.4	3
20	<i>In vivo</i> translational assessment of the GES genotype on the killing profile of ceftazidime, ceftazidime/avibactam and meropenem against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2803-2808.	3.0	7
21	Evaluation of Linezolid Pharmacokinetics in Critically Ill Obese Patients with Severe Skin and Soft Tissue Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	19
22	Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1
23	The paradoxical <i>in vivo</i> activity of β -lactams against metallo- β -lactamase-producing Enterobacterales is not restricted to carbapenems. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 684-691.	3.0	13
24	The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	2
25	Bactericidal In Vitro Activity of a Tissue-Achievable Concentration of Cefazolin against Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Surgical Infections</i> , 2021, 22, 447-449.	1.4	0
26	Efficacy of human-simulated exposures of meropenem/vaborbactam and meropenem against OXA-48 β -lactamase-producing Enterobacterales in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 184-188.	3.0	8
27	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against <i>Pseudomonas aeruginosa</i> from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 9.	3.8	9
28	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021, 41, 220-233.	2.6	61
29	Pharmacodynamics of Ceftibuten: An Assessment of an Oral Cephalosporin against Enterobacterales in a Neutropenic Murine Thigh Model. <i>Antibiotics</i> , 2021, 10, 201.	3.7	5
30	In Vivo Activity of WCK 4282 (High-Dose Cefepime/Tazobactam) against Serine- β -Lactamase-Producing Enterobacterales and <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
31	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106299.	2.5	23
32	Activity of β -Lactam Antibiotics against Metallo- β -Lactamase-Producing <i>Enterobacterales</i> in Animal Infection Models: a Current State of Affairs. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	16
33	Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab252.	0.9	11
34	A Novel Dosing Strategy of Ceftolozane/Tazobactam in a Patient Receiving Intermittent Hemodialysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab238.	0.9	2
35	In vitro synergy of ticarcillin/clavulanate in combination with aztreonam and ceftolozane/tazobactam against SPM-1-producing <i>Pseudomonas aeruginosa</i> strains. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 100, 115343.	1.8	2
36	Comment on: An update on cefepime and its future role in combination with novel β -lactamase inhibitors for MDR Enterobacterales and <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3326-3327.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Comparative <i>in vivo</i> activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing <i>Klebsiella pneumoniae</i> in the neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2310-2316.	3.0	5
38	Discrepancy in sustained efficacy and resistance emergence under human-simulated exposure of cefiderocol against <i>Stenotrophomonas maltophilia</i> between <i>in vitro</i> chemostat and <i>in vivo</i> murine infection models. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2615-2621.	3.0	9
39	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam <i>in vitro</i> Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2533-2541.	2.9	48
40	Efficacy assessment of lysin CF-296 in addition to daptomycin or vancomycin against <i>Staphylococcus aureus</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2622-2628.	3.0	2
41	Pharmacokinetics, Tissue Distribution, and Efficacy of VIO-001 (Meropenem/Piperacillin/Tazobactam) for Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia in Immunocompetent Rabbits with Chronic Indwelling Vascular Catheters. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0116821.	3.2	3
42	Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2902-2905.	3.0	30
43	Reply to Rennie, "Zinc Concentration Affects Metallo-Beta-Lactamase Susceptibility Testing of Enterobacterales". <i>Journal of Clinical Microbiology</i> , 2021, 59, e0121121.	3.9	1
44	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0120421.	3.2	6
45	Levofloxacin pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in a neutropenic murine thigh infection model: implications for susceptibility breakpoint revision. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 164-168.	3.0	12
46	Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in <i>Pseudomonas aeruginosa</i> : Validation in a Multicenter German Cohort. <i>Microbial Drug Resistance</i> , 2021, 27, 1243-1248.	2.0	5
47	Ceftolozane/tazobactam for refractory <i>P. aeruginosa</i> endocarditis: A case report and pharmacokinetic analysis. <i>Journal of Infection and Chemotherapy</i> , 2021, 28, 87-90.	1.7	2
48	Phenotypic/Genotypic Profile of OXA-10-Like-Harboring, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Using Validated Pharmacokinetic/Pharmacodynamic <i>In Vivo</i> Models To Further Evaluate Enzyme Functionality and Clinical Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0127421.	3.2	3
49	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial <i>Stenotrophomonas maltophilia</i> bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106395.	2.5	12
50	<i>In vivo</i> activity of WCK 4282 (high-dose cefepime/tazobactam) against serine β -lactamase-producing Enterobacterales and <i>Pseudomonas aeruginosa</i> in the neutropenic murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 993-1000.	3.0	6
51	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021, 50, 327-335.	0.4	2
52	Evaluation of Metallo- β -Lactamase Susceptibility Testing in a Physiologic Medium. <i>Microbiology Spectrum</i> , 2021, 9, e0167021.	3.0	3
53	Effect of Blood Product Resuscitation on the Pharmacokinetics of Ampicillin-Sulbactam during Orthotopic Liver Transplantation. <i>Surgical Infections</i> , 2021, , .	1.4	0
54	1103. Minocycline (MIN) Pharmacodynamics (PD) against <i>Stenotrophomonas maltophilia</i> (STM) in a Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2021, 8, S643-S643.	0.9	1

#	ARTICLE	IF	CITATIONS
55	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>Open Forum Infectious Diseases</i> , 2021, 8, S646-S646.	0.9	2
56	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021, 8, S147-S148.	0.9	0
57	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021, 8, S635-S635.	0.9	1
58	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against <i>Stenotrophomonas maltophilia</i> (STM). <i>Open Forum Infectious Diseases</i> , 2021, 8, S44-S44.	0.9	0
59	1241. In Vivo Efficacy of Meropenem Against Metallo- β -Lactamase (MBL)-Harboring <i>Pseudomonas aeruginosa</i> and Correlation to In Vitro Susceptibility Upon Addition of EDTA. <i>Open Forum Infectious Diseases</i> , 2021, 8, S710-S710.	0.9	0
60	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020, 70, 1240-1246.	5.8	29
61	Single β -lactams versus combinations as empiric therapy for infections with <i>Pseudomonas aeruginosa</i> : assessing the in vitro susceptibility. <i>Infectious Diseases</i> , 2020, 52, 33-38.	2.8	2
62	Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing <i>Pseudomonas aeruginosa</i> in a neutropenic murine lung infection model. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105838.	2.5	24
63	Monte Carlo Simulation Methodologies for β -Lactam/ β -Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 172-180.	2.0	8
64	Piperacillin-Tazobactam-Resistant/Third-Generation Cephalosporin-Susceptible <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates: Resistance Mechanisms and In vitro-In vivo Discordance. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105885.	2.5	18
65	Evaluation of the in vitro activity of WCK 5222 (cefepime/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: Expanding the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105863.	2.5	13
66	Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 330-340.	9.1	88
67	Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020, 39, 791-797.	2.9	51
68	Synergistic Activity of Exebacase (CF-301) in Addition to Daptomycin against <i>Staphylococcus aureus</i> in a Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
69	Variability in Zinc Concentration among Mueller-Hinton Broth Brands: Impact on Antimicrobial Susceptibility Testing of Metallo- β -Lactamase-Producing Enterobacteriaceae. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	17
70	Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant <i>Staphylococcus aureus</i> Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	1
71	Use of continuous-infusion ceftolozane/tazobactam for resistant Gram-negative bacterial infections: a retrospective analysis and brief review of the literature. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106158.	2.5	22
72	Augmented Renal Clearance and How to Augment Antibiotic Dosing. <i>Antibiotics</i> , 2020, 9, 393.	3.7	52

#	ARTICLE	IF	CITATIONS
73	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	4
74	EDTA-modified carbapenem inactivation method (eCIM) for detecting IMP Metallo- β -lactamase-producing <i>Pseudomonas aeruginosa</i> : an assessment of increasing EDTA concentrations. BMC Microbiology, 2020, 20, 220.	3.3	6
75	Development of an HPLC Method for the Determination of Meropenem/Vaborbactam in Biological and Aqueous Matrixes. Journal of Chromatographic Science, 2020, 58, 726-730.	1.4	5
76	Imipenem/Cilastatin/Relebactam Alone and in Combination against <i>Pseudomonas aeruginosa</i> in the <i>In Vitro</i> Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	8
77	Evaluation of the Xpert Carba-R NxG Assay for Detection of Carbapenemase Genes in a Global Challenge Set of <i>Pseudomonas aeruginosa</i> Isolates. Journal of Clinical Microbiology, 2020, 58, .	3.9	13
78	Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> . Antibiotics, 2020, 9, 738.	3.7	12
79	<i>In vivo</i> pharmacodynamics of new-generation β -lactamase inhibitor taniborbactam (formerly) TJEQq11.0784314. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3601-3610.	3.0	23
80	Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective. Expert Review of Anti-Infective Therapy, 2020, 18, 721-740.	4.4	12
81	<i>In vivo</i> activity of human-simulated regimens of imipenem alone and in combination with relebactam against <i>Pseudomonas aeruginosa</i> in the murine thigh infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2197-2205.	3.0	7
82	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020, 42, 606-613.	2.5	9
83	Clinical pharmacokinetics of ceftolozane and tazobactam in an obese patient receiving continuous venovenous haemodiafiltration: A patient case and literature review. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 83-85.	2.2	8
84	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1546-1553.	3.0	43
85	Carbapenem-Resistant Enterobacterales, Carbapenem Resistant Organisms, Carbapenemase-Producing Enterobacterales, and Carbapenemase-Producing Organisms: Terminology Past its "Sell-By Date" in an Era of New Antibiotics and Regional Carbapenemase Epidemiology. <i>Clinical Infectious Diseases</i> , 2020, 71, 1776-1782.	5.8	47
86	Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology. <i>Current Infectious Disease Reports</i> , 2020, 22, 6.	3.0	37
87	Metallo- β -lactamase resistance in Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility testing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 997-1005.	3.0	38
88	Pharmacodynamic comparison of different antimicrobial regimens against <i>Staphylococcus aureus</i> bloodstream infections with elevated vancomycin minimum inhibitory concentration. <i>BMC Infectious Diseases</i> , 2020, 20, 74.	2.9	3
89	Comparative Evaluation of the <i>In Vitro</i> Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	15
90	<i>In vitro</i> synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1874-1878.	3.0	23

#	ARTICLE	IF	CITATIONS
91	Evaluation of the EDTA-Modified Carbapenem Inactivation Method for Detecting Metallo- β -Lactamase-Producing <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	58
92	1302. Cefiderocol Population Pharmacokinetics and Probability of Target Attainment in Plasma and Epithelial Lining Fluid in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, S665-S665.	0.9	4
93	1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. <i>Open Forum Infectious Diseases</i> , 2020, 7, S668-S668.	0.9	4
94	Efficacy and Safety of Eravacycline in Obese Patients: A Post Hoc Analysis of Pooled Data From the IGNITE1 and IGNITE4 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa548.	0.9	4
95	Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
96	1264. Assessment of In Vivo Efficacy of CF-296 in addition to Vancomycin (VAN) and Daptomycin (DAP) against <i>Staphylococcus aureus</i> in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S648-S649.	0.9	0
97	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020, 7, S667-S667.	0.9	0
98	1245. <i>In Vivo</i> Efficacy of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) Against β -Lactamase-Producing (BLP) Gram-Negative Bacteria in a Neutropenic Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S641-S641.	0.9	0
99	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against <i>pseudomonas Aeruginosa</i> (psa) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020, 7, S7-S8.	0.9	0
100	656. Development and Application of a Pragmatic Algorithm for the Detection of Carbapenemase-Producing <i>Pseudomonas aeruginosa</i> (CP-PA). <i>Open Forum Infectious Diseases</i> , 2020, 7, S384-S385.	0.9	0
101	1312. Metallo- β -lactamase-Producing Enterobacterales (MBL-EB): Is it Time to Rethink Our Assessment Tools?. <i>Open Forum Infectious Diseases</i> , 2020, 7, S668-S668.	0.9	0
102	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against <i>Pseudomonas aeruginosa</i> (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020, 7, S797-S797.	0.9	0
103	1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime) Tj ETQq1 1 0.784314 rgB Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S640-S641.	0.9	0
104	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against <i>Pseudomonas aeruginosa</i> (PSA) in the <i>In Vitro</i> Pharmacodynamic Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S667-S667.	0.9	0
105	1299. <i>In Vitro</i> - <i>In Vivo</i> Discordance with β -lactams against Metallo- β -lactamase-Producing Enterobacterales: Implications for Susceptibility Testing. <i>Open Forum Infectious Diseases</i> , 2020, 7, S664-S664.	0.9	0
106	1215. Evaluation of the Carba-R NxG Assay in a Global Challenge Set of <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2020, 7, S629-S629.	0.9	0
107	1296. Efficacy of Human-Simulated Exposures of Meropenem/Vaborbactam (MVB) and Meropenem (MEM) against OXA-48 β -lactamase-producing Enterobacterales in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2020, 7, S663-S663.	0.9	0
108	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020, 7, S670-S670.	0.9	1

#	ARTICLE	IF	CITATIONS
109	In vitro potency of antipseudomonal β -lactams against blood and respiratory isolates of <i>P. aeruginosa</i> collected from US hospitals. <i>Journal of Thoracic Disease</i> , 2019, 11, 1896-1902.	1.4	13
110	Pharmacokinetics-pharmacodynamics of β -lactamase inhibitors: are we missing the target?. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 571-582.	4.4	17
111	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	6
112	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β -Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	5
113	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019, 23, 251.	5.8	17
114	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019, 41, 1453-1462.	2.5	7
115	Ceftolozane-Tazobactam in the Treatment of Experimental <i>Pseudomonas aeruginosa</i> Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	10
116	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019, 8, 383-396.	4.0	14
117	<i>In Vivo</i> Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	27
118	<i>In Vitro</i> Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	24
119	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 346-350.	2.5	9
120	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019, 41, 2162-2170.	2.5	8
121	Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. <i>American Journal of Health-System Pharmacy</i> , 2019, 77, 9-13.	1.0	4
122	1544. Efficacy of Human-Simulated Cefiderocol Exposure Against Gram-Negative Bacteria in an Iron-Overloaded Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2019, 6, S563-S563.	0.9	0
123	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019, 2, 444-445.	1.0	0
124	Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR <i>Pseudomonas aeruginosa</i> in a neutropenic murine pneumonia model. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 75, 149-155.	3.0	20
125	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	6
126	Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β -Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	16

#	ARTICLE	IF	CITATIONS
127	In vitro investigation of synergy among fosfomycin and parenteral antimicrobials against carbapenemase-producing Enterobacteriaceae. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 216-220.	1.8	10
128	Carbapenem-Nonsusceptible <i>Pseudomonas aeruginosa</i> Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	29
129	<i>In Vivo</i> Pharmacodynamic Profile of Ceftibuten-Clavulanate Combination against Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	20
130	<i>In Vitro</i> Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	8
131	In vitro activity of ampicillin and ceftriaxone against ampicillin-susceptible <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2269-2273.	3.0	12
132	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 698-702.	2.5	3
133	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019, 69, 903-904.	5.8	1
134	Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis. <i>American Journal of Health-System Pharmacy</i> , 2019, 76, 501-504.	1.0	20
135	Development of an HPLC-MS/MS method for the determination of ceftolozane/tazobactam in bronchoalveolar lavage fluid. <i>Future Science OA</i> , 2019, 5, FSO352.	1.9	5
136	1533. Is Cation-Adjusted Mueller-Hinton Broth (CAMHB) Appropriate for Metallo- β -lactamase (MBL) Susceptibility Testing? Novel Insights in In Vitro-In Vivo Discordance Among MBL-Producing Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2019, 6, S558-S559.	0.9	0
137	682. In Vivo Pharmacodynamics of VNRX-7145 in the Neutropenic Murine Thigh Infection Model When Administered in Combination with Humanized Exposures of Twice Daily Ceftibuten (CTB) Against Serine β -Lactamase-Producing Enterobacteriaceae (SBL-EB). <i>Open Forum Infectious Diseases</i> , 2019, 6, S311-S311.	0.9	2
138	675. Efficacy of Human-Simulated Bronchopulmonary Exposures of Cefepime and Zidebactam (WCK) Tj ETQq0 0 0 rgBT /Overlock 10 Tf Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2019, 6, S308-S308.	0.9	0
139	725. WCK 5222 (Cefepime/Zidebactam): An In Vitro Assessment of Activity Compared with Current Dual-Antibiotic Options Against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2019, 6, S325-S325.	0.9	0
140	1550. PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models. <i>Open Forum Infectious Diseases</i> , 2019, 6, S565-S566.	0.9	1
141	1553. Human-Simulated Pharmacokinetic Profiles of Cefiderocol and Meropenem Are Conserved in Murine Models of Thigh Infection With or Without Iron Overload. <i>Open Forum Infectious Diseases</i> , 2019, 6, S567-S567.	0.9	0
142	685. An In Vitro Investigation of WCK 5222 (Cefepime/Zidebactam) and Currently Available Combination Antibiotic Regimens Against Enterobacteriaceae That Co-express Serine- β -Lactamase (SBL) and Metallo- β -Lactamase (MBL) Enzymes. <i>Open Forum Infectious Diseases</i> , 2019, 6, S311-S312.	0.9	0
143	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	5
144	450. Evaluation of Linezolid Pharmacokinetics in Obese Patients with Severe Skin and Soft-Tissue Infections. <i>Open Forum Infectious Diseases</i> , 2019, 6, S221-S221.	0.9	0

#	ARTICLE	IF	CITATIONS
145	Comparative <i>In Vivo</i> Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against <i>Stenotrophomonas maltophilia</i> in the Murine Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	27
146	Efficacy of Humanized Cefiderocol Exposure Is Unaltered by Host Iron Overload in the Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	13
147	Development of Neutropenic Murine Models of Iron Overload and Depletion To Study the Efficacy of Siderophore-Antibiotic Conjugates. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	13
148	Pharmacokinetics of Cefazolin and Vancomycin in Infants Undergoing Open-Heart Surgery With Cardiopulmonary Bypass. <i>Anesthesia and Analgesia</i> , 2019, 128, 935-943.	2.2	8
149	Nebulized Amikacin and Fosfomycin for Severe <i>Pseudomonas aeruginosa</i> Pneumonia. <i>Critical Care Medicine</i> , 2019, 47, e470-e477.	0.9	15
150	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019, 68, 1650-1657.	5.8	42
151	Comparative efficacy of human-simulated epithelial lining fluid exposures of tedizolid, linezolid and vancomycin in neutropenic and immunocompetent murine models of staphylococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 970-977.	3.0	7
152	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019, 20, 55-61.	1.4	37
153	In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
154	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	5
155	Efficacy of Humanized Cefiderocol Exposures over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	25
156	Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>Journal of Medical Microbiology</i> , 2019, 68, 893-897.	1.8	15
157	Humanized Exposures of Cefiderocol, a Siderophore Cephalosporin, Display Sustained in vivo Activity against Siderophore-Resistant <i>Pseudomonas aeruginosa</i> . <i>Pharmacology</i> , 2018, 101, 278-284.	2.2	35
158	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an <i>In Vitro</i> Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
159	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 294-297.	1.8	16
160	Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 325-338.	4.1	32
161	Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic/pharmacodynamic analysis. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 727-732.	2.5	18
162	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 397-408.	1.8	24

#	ARTICLE	IF	CITATIONS
163	Subcutaneous ceftazolin to reduce surgical site infections in a porcine model. <i>Journal of Surgical Research</i> , 2018, 224, 156-159.	1.6	2
164	Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 942-952.	3.0	36
165	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018, 40, 261-269.	2.5	16
166	Humanized Exposures of a β -Lactam- β -Lactamase Inhibitor, Tazobactam, versus Non- β -Lactam- β -Lactamase Inhibitor, Avibactam, with or without Colistin, against <i>Acinetobacter baumannii</i> in Murine Thigh and Lung Infection Models. <i>Pharmacology</i> , 2018, 101, 255-261.	2.2	8
167	Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a <i>Pseudomonas aeruginosa</i> neutropenic murine thigh model. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 206-212.	2.5	41
168	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via <i>In Vivo</i> Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
169	Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant <i>pseudomonas</i> infection and renal insufficiency. <i>Respiratory Medicine Case Reports</i> , 2018, 23, 8-9.	0.4	21
170	1336. Assessment of the <i>In Vivo</i> Efficacy of WCK 5222 (Cefepime-Zidebactam) Against Carbapenems-Resistant <i>Acinetobacter baumannii</i> (CR-ACBN) in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018, 5, S408-S408.	0.9	1
171	1368. Assessment of the <i>In Vivo</i> Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposure of Meropenem/Nacubactam (MEM/NAC) Combination Against β -Lactamase-Producing Enterobacteriaceae in Neutropenic Lung Infection Model. <i>Open Forum Infectious Diseases</i> , 2018, 5, S419-S419.	0.9	2
172	1397. Comparative Efficacy of Human-Simulated Epithelial Lining Fluid (ELF) Exposures of Tedizolid (TZD) Against Methicillin-resistant <i>Staphylococcus Aureus</i> (MRSA) in Neutropenic (I ⁺) vs. Immunocompetent (I ⁺) Murine Models of Pneumonia. <i>Open Forum Infectious Diseases</i> , 2018, 5, S430-S430.	0.9	0
173	1405. Efficacy of the Human-Simulated Regimen (HSR) of Cefepime (FEP)/VNRX-5133 Combination Against Serine β -Lactamase-Producing Gram-negative Bacteria in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018, 5, S432-S433.	0.9	3
174	2175. <i>In vitro</i> Potency of Ceftolozane/Tazobactam and Other Antipseudomonal β -Lactams Against <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S642-S642.	0.9	0
175	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018, 18, 932.	2.2	11
176	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy206.	0.9	4
177	2176. Single β -Lactams v. Combination Regimens: Assessing the Probability that an Active Agent Would be Selected When Considering Empiric Therapy for <i>P. aeruginosa</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, S642-S643.	0.9	0
178	2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours Against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2018, 5, S712-S712.	0.9	0
179	Optimizing Antibiotic Administration for Pneumonia. <i>Clinics in Chest Medicine</i> , 2018, 39, 837-852.	2.1	3
180	Epidemiology of Bloodstream Infections Caused by <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> That Are Piperacillin-Tazobactam-Nonsusceptible but Ceftriaxone-Susceptible. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy300.	0.9	13

#	ARTICLE	IF	CITATIONS
181	In Vitro Activity of Newer and Conventional Antimicrobial Agents, Including Fosfomycin and Colistin, against Selected Gram-Negative Bacilli in Kuwait. <i>Pathogens</i> , 2018, 7, 75.	2.8	12
182	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, e36-e44.	1.0	12
183	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1048-1056.	1.0	15
184	Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant <i>Acinetobacter baumannii</i> in the Neutropenic Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	36
185	Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	42
186	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	11
187	Review of antimicrobial use and considerations in the elderly population. <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 657-667.	2.9	52
188	<i>In Vivo</i> Efficacy of Meropenem with a Novel Non- β -Lactam β -Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	40
189	Management of Pediatric Acute Hematogenous Osteomyelitis, Part <sc>II</sc>: A Focus on Methicillin-Resistant <i>Staphylococcus aureus</i> , Current and Emerging Therapies. <i>Pharmacotherapy</i> , 2018, 38, 1021-1037.	2.6	12
190	Pharmacodynamics of Daptomycin against <i>Enterococcus faecium</i> and <i>Enterococcus faecalis</i> in the Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	17
191	Assessing the in vitro activity of ceftazidime/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: Defining the zone of hope. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 688-691.	2.5	36
192	Feasibility of routine synergy testing using antibiotic gradient diffusion strips in the clinical laboratory. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2264-2265.	3.0	7
193	Defining the potency of amikacin against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Pseudomonas aeruginosa</i> , and <i>Acinetobacter baumannii</i> derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 783-790.	2.7	17
194	<i>In Vivo</i> Efficacy of Plazomicin Alone or in Combination with Meropenem or Tigecycline against Enterobacteriaceae Isolates Exhibiting Various Resistance Mechanisms in an Immunocompetent Murine Septicemia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
195	Assessment of the <i>In Vivo</i> Activity of SPR741 in Combination with Azithromycin against Multidrug-Resistant Enterobacteriaceae Isolates in the Neutropenic Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	18
196	Management of Pediatric Acute Hematogenous Osteomyelitis, Part I: Antimicrobial Stewardship Approach and Review of Therapies for Methicillin-Susceptible <i>Staphylococcus aureus</i> , <i>Streptococcus pyogenes</i> , and <i>Kingella kingae</i> . <i>Pharmacotherapy</i> , 2018, 38, 947-966.	2.6	17
197	Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children. <i>Current Pediatric Reviews</i> , 2018, 14, 97-109.	0.8	12
198	Detection of Piperacillin-Tazobactam-Resistant/Pan- β -Lactam-Susceptible <i>Escherichia coli</i> with Current Automated Susceptibility Test Systems. <i>Infection Control and Hospital Epidemiology</i> , 2017, 38, 379-380.	1.8	7

#	ARTICLE	IF	CITATIONS
199	Epidemiology, treatment, and economics of patients presenting to the emergency department for skin and soft tissue infections. <i>Hospital Practice</i> (1995), 2017, 45, 9-15.	1.0	21
200	The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. <i>Intensive Care Medicine</i> , 2017, 43, 1187-1197.	8.2	103
201	Anti-staphylococcal activity resulting from epithelial lining fluid (ELF) concentrations of amikacin inhale administered via the pulmonary drug delivery system. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2017, 16, 2.	3.8	6
202	Obesity and skin and soft tissue infections: how to optimize antimicrobial usage for prevention and treatment?. <i>Current Opinion in Infectious Diseases</i> , 2017, 30, 180-191.	3.1	25
203	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 705-714.	3.3	10
204	In vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant <i>Pseudomonas aeruginosa</i> from Pediatric Cystic Fibrosis Patients. <i>Infectious Diseases and Therapy</i> , 2017, 6, 129-136.	4.0	18
205	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 712-719.	2.0	22
206	Physical compatibility of ceftolozane+tazobactam with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e47-e54.	1.0	9
207	Comparative <i>In Vivo</i> Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine <i>Streptococcus pneumoniae</i> Lung Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
208	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, e55-e63.	1.0	3
209	Effects of Clinically Meaningful Concentrations of Antipseudomonal β -Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3502-3512.	3.9	6
210	Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	80
211	Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum- β -Lactamase-Producing <i>Escherichia coli</i> in a Murine Model of Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	5
212	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
213	<i>In Vitro</i> Comparison of Ceftolozane-Tazobactam to Traditional Beta-Lactams and Ceftolozane-Tazobactam as an Alternative to Combination Antimicrobial Therapy for <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	30
214	Clinical and economic implications of urinary tract infections. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 377-383.	1.4	13
215	Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects. <i>Drugs</i> , 2017, 77, 1399-1412.	10.9	6
216	Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhale alone and in combination with meropenem against <i>Acinetobacter baumannii</i> . <i>Infectious Diseases</i> , 2017, 49, 831-839.	2.8	6

#	ARTICLE	IF	CITATIONS
235	Human-Simulated Exposure and Pharmacodynamic (PD) Assessment of Tedizolid (TZD) Against <i>Streptococcus pneumoniae</i> in an Immunocompetent Murine Lung Infection Model. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
236	Comparative In Vivo Efficacy of Human-Simulated Exposures of Tedizolid (TZD) in Neutropenic (I-) versus Immunocompetent (I+) Murine <i>Streptococcus pneumoniae</i> Lung Infection Model. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
237	In Vivo Activity of Humanized Exposures of Piperacillin-Tazobactam (TZP) against TZP-Resistant/Pan- β -Lactam-Susceptible (TZP-R/PBL-S) <i>Escherichia coli</i> in a Murine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
238	Prevalence and Risk Factors of a Novel Piperacillin/Tazobactam-Nonsusceptible, β -Lactam-Pan-Susceptible (TZP-NS/BL-PS) Phenotype in Enterobacteriaceae. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
239	Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. <i>Pharmacotherapy</i> , 2016, 36, e30-e33.	2.6	41
240	In vitro potency of amikacin and comparators against <i>E. coli</i> , <i>K. pneumoniae</i> and <i>P. aeruginosa</i> respiratory and blood isolates. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 39.	3.8	24
241	Successful Treatment of Multi-Drug Resistant <i>Pseudomonas aeruginosa</i> Bacteremia with the Recommended Renally Adjusted Ceftolozane/Tazobactam Regimen. <i>Infectious Diseases and Therapy</i> , 2016, 5, 73-79.	4.0	20
242	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 215-218.	1.8	26
243	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016, 37, 583-589.	1.8	27
244	Can we improve clinical outcomes in patients with pneumonia treated with antibiotics in the intensive care unit?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 907-918.	2.5	10
245	Evaluation of a disease state management guideline for urinary tract infection. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 451-456.	2.5	5
246	Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes. <i>Journal of Chromatographic Science</i> , 2016, 54, 1037-1040.	1.4	34
247	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> : Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 955-961.	3.2	5
248	Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. <i>Annals of Intensive Care</i> , 2016, 6, 35.	4.6	59
249	Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in a Child with Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5627-5630.	3.2	23
250	Ceftolozane/tazobactam pharmacokinetic/pharmacodynamicâ€derived dose justification for phase 3 studies in patients with nosocomial pneumonia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 56-66.	2.0	135
251	Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure <i>In Vivo</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5072-5075.	3.2	22
252	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6578-6584.	3.2	35

#	ARTICLE	IF	CITATIONS
253	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 342-343.	2.5	35
254	Clinical pathway for moderate to severe acute bacterial skin and skin structure infections from a US perspective: a roundtable discussion. <i>Hospital Practice (1995)</i> , 2016, 44, 183-189.	1.0	11
255	Continuous and Prolonged Intravenous β -Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016, 29, 759-772.	13.6	51
256	Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 535-541.	2.5	42
257	Physical compatibility of tedizolid phosphate with selected i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 1769-1776.	1.0	6
258	Humanized Exposures of a β -Lactam/ β -Lactamase Inhibitor (BL-BLI), Tazobactam (TZB), Versus a Non- β -Lactam/ β -Lactamase Inhibitor, Avibactam (AVI), With or Without Colistin (CST), Against <i>Acinetobacter baumannii</i> (AB) in Murine Thigh and Lung Infection Models. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
259	Pharmacodynamics of carbapenems for the treatment of <i>Pseudomonas aeruginosa</i> ventilator-associated pneumonia: associations with clinical outcome and recurrence. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2534-2537.	3.0	26
260	Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1039-1045.	3.1	15
261	In vivo efficacy of humanized high dose meropenem and comparators against <i>Pseudomonas aeruginosa</i> isolates producing verona integron-encoded metallo- β -lactamase (VIM). <i>Heliyon</i> , 2016, 2, e00121.	3.2	1
262	A pilot study to assess bacterial and toxin reduction in patients with <i>Clostridium difficile</i> infection given fidaxomicin or vancomycin. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2016, 15, 22.	3.8	13
263	Antibacterial Efficacy of Eravacycline <i>In Vivo</i> against Gram-Positive and Gram-Negative Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5001-5005.	3.2	42
264	Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: Part I gram positive bacteria. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 267-280.	3.3	16
265	Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 428-437.	3.0	14
266	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1401-1410.	3.2	51
267	Poor outcomes of empiric ceftriaxone \pm azithromycin for community-acquired pneumonia caused by methicillin-susceptible <i>Staphylococcus aureus</i> . <i>Internal and Emergency Medicine</i> , 2016, 11, 545-551.	2.0	5
268	Effect of Body Weight on Cefazolin and Vancomycin Trabecular Bone Concentrations in Patients Undergoing Total Joint Arthroplasty. <i>Surgical Infections</i> , 2016, 17, 71-77.	1.4	15
269	<i>In Vitro</i> Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 222-228.	3.2	3
270	Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis. <i>Clinical Drug Investigation</i> , 2016, 36, 157-168.	2.2	17

#	ARTICLE	IF	CITATIONS
271	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 247-248.	2.5	4
272	An exploratory analysis of the ability of a cefepime trough concentration greater than 22Âmg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016, 22, 78-83.	1.7	31
273	Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1899-1901.	3.2	35
274	Epidemiology and economics of adult patients hospitalized with urinary tract infections. <i>Hospital Practice (1995)</i> , 2016, 44, 33-40.	1.0	29
275	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 459-476.	3.1	22
276	Clinafloxacin for Treatment of Burkholderia cenocepacia Infection in a Cystic Fibrosis Patient. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1-5.	3.2	13
277	Isolation and quantitation of Clostridium difficile in aqueous and fecal matter using two types of selective media. <i>Journal of Microbiology, Immunology and Infection</i> , 2016, 49, 445-447.	3.1	6
278	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 189-195.	3.0	25
279	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 256-9.	0.1	1
280	Lack of Correlation between Bristol Stool Scale and Quantitative Bacterial Load in Clostridium difficile Infection. <i>Infectious Diseases: Research and Treatment</i> , 2015, 8, IDRT.S23079.	1.7	5
281	Making a Case for Pediatric Antimicrobial Stewardship Programs. <i>Pharmacotherapy</i> , 2015, 35, 1026-1036.	2.6	31
282	Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. <i>Infection and Drug Resistance</i> , 2015, 8, 297.	2.7	43
283	Assessing the Surrogate Susceptibility of Oxacillin and Cefoxitin for Commonly Utilized Parenteral Agents against Methicillin-Susceptible Staphylococcus aureus: Focus on Ceftriaxone Discordance between Predictive Susceptibility and in Vivo Exposures. <i>Pathogens</i> , 2015, 4, 599-605.	2.8	10
284	In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae. <i>Pathogens</i> , 2015, 4, 620-625.	2.8	32
285	Potential of Antibacterial Activity of the MB-1 Siderophore-Monobactam Conjugate Using an Efflux Pump Inhibitor. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2439-2442.	3.2	29
286	Pharmacodynamic Profile of GSK2140944 against Methicillin-Resistant Staphylococcus aureus in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4956-4961.	3.2	23
287	Validation of a Dosing Strategy for Cefazolin for Surgery Requiring Cardiopulmonary Bypass. <i>Surgical Infections</i> , 2015, 16, 829-832.	1.4	8
288	Defining Extended Spectrum $\hat{2}$ -Lactamases: Implications of Minimum Inhibitory Concentration-Based Screening Versus Clavulanate Confirmation Testing. <i>Infectious Diseases and Therapy</i> , 2015, 4, 513-518.	4.0	2

#	ARTICLE	IF	CITATIONS
289	<i>In Vivo</i> Activities of Simulated Human Doses of Cefepime and Cefepime-AA1101 against Multidrug-Resistant Gram-Negative Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2688-2694.	3.2	44
290	Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> From US Hospitals. <i>Clinical Therapeutics</i> , 2015, 37, 1564-1571.	2.5	52
291	Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2862-2869.	3.0	98
292	Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> . <i>Journal of Urology</i> , 2015, 194, 563-570.	0.4	32
293	Increased 3-gram cefazolin dosing for cesarean delivery prophylaxis in obese women. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 415.e1-415.e8.	1.3	120
294	Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1261-1273.	4.1	8
295	Discovery and Characterization of a Water-Soluble Prodrug of a Dual Inhibitor of Bacterial DNA Gyrase and Topoisomerase IV. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 822-826.	2.8	19
296	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 512-518.	2.5	9
297	Impact of Revised Cefepime CLSI Breakpoints on <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> Susceptibility and Potential Impact If Applied to <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , 2015, 53, 1712-1714.	3.9	13
298	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 53-55.	1.8	34
299	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2064-2067.	3.0	20
300	Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in <i>Pseudomonas aeruginosa</i> : Assessing the Risk for Resistance and Attenuated Efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7743-7752.	3.2	64
301	Efficacy of Humanized High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae Isolates Producing Verona Integron-Encoded Metallo- β -Lactamase (VIM) in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7145-7147.	3.2	15
302	Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in <i>Clostridium difficile</i> infection. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 205-208.	2.5	21
303	Demography and burden of care associated with patients readmitted for urinary tract infection. <i>Journal of Microbiology, Immunology and Infection</i> , 2015, 48, 517-524.	3.1	12
304	<i>In Vivo</i> Efficacy of Humanized Exposures of Ceftazidime-Avibactam in Comparison with Ceftazidime against Contemporary Enterobacteriaceae Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6913-6919.	3.2	42
305	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014, 3, 269-279.	4.0	16
306	Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1359-1364.	3.2	68

#	ARTICLE	IF	CITATIONS
307	Unexpected <i>In Vivo</i> Activity of Ceftazidime Alone and in Combination with Avibactam against New Delhi Metallo- β -Lactamase-Producing Enterobacteriaceae in a Murine Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7007-7009.	3.2	33
308	Comparison of <i>In Vivo</i> and <i>In Vitro</i> Pharmacodynamics of a Humanized Regimen of 600 Milligrams of Ceftaroline Fosamil Every 12 Hours against <i>Staphylococcus aureus</i> at Initial Inocula of 10^{10} and 10^8 CFU per Milliliter. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6931-6933.	3.2	11
309	<i>In Vivo</i> Efficacy of Human Simulated Regimens of Carbapenems and Comparator Agents against NDM-1-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1671-1677.	3.2	32
310	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and ~ 20 $^{\circ}$ C. <i>American Journal of Health-System Pharmacy</i> , 2014, 71, 1480-1484.	1.0	6
311	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2177-2181.	2.2	8
312	Humanized tissue pharmacodynamics of cefazolin against commonly isolated pathogens in skin and skin structure infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2443-2447.	3.0	7
313	Prolonging β -lactam infusion: A review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 105-113.	2.5	75
314	<i>In Vitro</i> Pharmacodynamics of Polymyxin B and Tigecycline Alone and in Combination against Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 874-879.	3.2	65
315	Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 508-513.	2.5	1
316	To Add or Not To Add Polysorbate 80: Impact on Colistin MICs for Clinical Strains of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> and Quality Controls. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3810-3810.	3.9	17
317	Pharmacodynamic profile of commonly utilised parenteral therapies against methicillin-susceptible and methicillin-resistant <i>Staphylococcus aureus</i> collected from US hospitals. <i>International Journal of Antimicrobial Agents</i> , 2014, 44, 235-241.	2.5	38
318	<i>In Vitro</i> Activity of Human-Simulated Epithelial Lining Fluid Exposures of Ceftaroline, Ceftriaxone, and Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7520-7526.	3.2	17
319	Pharmacodynamic profiling of modithromycin: Assessment in a pneumococcal murine pneumonia model. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 540-546.	2.5	2
320	Efficacies of Ceftazidime-Avibactam and Ceftazidime against <i>Pseudomonas aeruginosa</i> in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1365-1371.	3.2	55
321	In vitro microdialysis membrane efficiency of broad-spectrum antibiotics in combination and alone. <i>Clinical Pharmacology: Advances and Applications</i> , 2014, 6, 97.	1.2	4
322	Pharmacokinetics of Intravenous Linezolid in Moderately to Morbidly Obese Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1144-1149.	3.2	56
323	Human Simulated Studies of Aztreonam and Aztreonam-Avibactam To Evaluate Activity against Challenging Gram-Negative Organisms, Including Metallo- β -Lactamase Producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3299-3306.	3.2	92
324	Efficacy of Humanized Carbapenem Exposures against New Delhi Metallo- β -Lactamase (NDM-1)-Producing Enterobacteriaceae in a Murine Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3936-3940.	3.2	32

#	ARTICLE	IF	CITATIONS
325	Reply to "Double-Carbapenem Therapy Not Proven To Be More Active than Carbapenem Monotherapy against KPC-Positive <i>Klebsiella pneumoniae</i> ". <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4038-4038.	3.2	2
326	Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2012, 25, 94-98.	2.6	18
327	Carbapenem stewardship: does ertapenem affect <i>Pseudomonas</i> susceptibility to other carbapenems? A review of the evidence. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 11-15.	2.5	57
328	Cefepime Dosing in the Morbidly Obese Patient Population. <i>Obesity Surgery</i> , 2012, 22, 465-471.	2.1	37
329	Current challenges in the management of the infected patient. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, S1-S10.	3.1	35
330	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011, 37, 632-638.	8.2	90
331	In Vivo Efficacy of a Human-Simulated Regimen of Ceftazidime Combined with NXL104 against Extended-Spectrum- β -Lactamase (ESBL)-Producing and Non-ESBL-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3220-3225.	3.2	52
332	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis " A review of 3 cases. <i>Respiratory Medicine CME</i> , 2010, 3, 146-149.	0.1	13
333	Clinical Pharmacodynamics of Cefepime in Patients Infected with <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1111-1116.	3.2	110
334	Therapeutic Options for Diabetic Foot Infections. <i>Journal of the American Podiatric Medical Association</i> , 2010, 100, 52-63.	0.3	34
335	Pharmacokinetics of Ticlopidine in the Rabbit. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 51, 393-396.	2.4	3
336	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2062.	0.1	0
337	Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1213-1222.	1.8	24
338	Population Pharmacokinetics of High-Dose, Prolonged-Infusion Cefepime in Adult Critically Ill Patients with Ventilator-Associated Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1476-1481.	3.2	114
339	What Is the 360-Degree Approach to Defining Success for VAP?. <i>Journal of Managed Care Pharmacy</i> , 2009, 15, 3-4.	2.2	0
340	Carbapenems: a potent class of antibiotics. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 23-37.	1.8	159
341	Pharmacodynamic optimization of β -lactams in the patient care setting. <i>Critical Care</i> , 2008, 12, S2.	5.8	47
342	Bugs versus drugs: What is the pharmacist's challenge?. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S2-S3.	1.0	2

#	ARTICLE	IF	CITATIONS
343	Influence of automated screening and confirmation of extended-spectrum $\hat{2}$ -lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. <i>Journal of Medical Microbiology</i> , 2008, 57, 1147-1151.	1.8	0
344	Pharmacokinetic and Pharmacodynamic Properties of Meropenem. <i>Clinical Infectious Diseases</i> , 2008, 47, S32-S40.	5.8	167
345	Pharmacokinetics of dalbavancin in plasma and skin blister fluid. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 681-684.	3.0	61
346	Clinical Pharmacodynamics of Meropenem in Patients with Lower Respiratory Tract Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1725-1730.	3.2	254
347	Treatment of <i>Serratia marcescens</i> Meningitis with Prolonged Infusion of Meropenem. <i>Annals of Pharmacotherapy</i> , 2007, 41, 1077-1081.	1.9	21
348	Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum- $\hat{2}$ -Lactamase-Producing <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in a Neutropenic Mouse Thigh Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1481-1486.	3.2	55
349	Empiric therapy for secondary peritonitis: A pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007, 29, 889-899.	2.5	12
350	Comparative in vivo efficacy of meropenem, imipenem, and cefepime against <i>Pseudomonas aeruginosa</i> expressing MexA-MexB-OprM efflux pumps. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 153-161.	1.8	55
351	Pharmacokinetics of Cefprozil in Plasma and Middle Ear Fluid. <i>Paediatric Drugs</i> , 2007, 9, 119-123.	3.1	11
352	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 452-457.	2.5	28
353	Employing pharmacokinetic and pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. <i>Brazilian Journal of Microbiology</i> , 2007, 38, 183-193.	2.0	10
354	Cefepime pharmacodynamics in patients with extended spectrum $\hat{2}$ -lactamase (ESBL) and non-ESBL infections. <i>Journal of Infection</i> , 2007, 54, 463-468.	3.3	49
355	Population Pharmacokinetic Analysis and Dosing Regimen Optimization of Meropenem in Adult Patients. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1171-1178.	2.0	143
356	Comparison of clarithromycin and ciprofloxacin therapy for <i>Bacillus anthracis</i> Sterne infection in mice with or without ^{60}Co gamma-photon irradiation. <i>Journal of Medical Microbiology</i> , 2005, 54, 1157-1162.	1.8	4
357	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 388-395.	3.0	98
358	Pharmacodynamics of antimicrobials: treatment optimisation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 351-361.	3.3	22
359	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004, 39, 1069-1075.	1.0	1
360	Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 229-235.	1.8	8

#	ARTICLE	IF	CITATIONS
361	Empiric Treatment of Multidrug-Resistant <i>Burkholderia cepacia</i> Lung Exacerbation in a Patient with Cystic Fibrosis: Application of Pharmacodynamic Concepts to Meropenem Therapy. <i>Pharmacotherapy</i> , 2004, 24, 1641-1645.	2.6	35
362	Meropenem Administered as a Prolonged Infusion to Treat Serious Gram-Negative Central Nervous System Infections. <i>Pharmacotherapy</i> , 2004, 24, 803-807.	2.6	25
363	Optimizing Efficacy in CARTIs: Introduction. <i>Annals of Pharmacotherapy</i> , 2004, 38, S7-S7.	1.9	0
364	Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections. <i>American Journal of Managed Care</i> , 2004, 10, S381-8.	1.1	3
365	Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling. <i>Journal of Infection and Chemotherapy</i> , 2003, 9, 292-296.	1.7	84
366	Influence of Sex on the Pharmacokinetic Interaction of Fleroxacin and Ciprofloxacin with Caffeine. <i>Clinical Pharmacokinetics</i> , 2003, 42, 985-996.	3.5	12
367	Pharmacodynamics of a Novel Des-F(6)-Quinolone, BMS-284756, against <i>Streptococcus pneumoniae</i> in the Thigh Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1630-1635.	3.2	15
368	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, 565-568.	1.0	36
369	Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 61-70.	3.0	42
370	Maximizing Outcomes in Respiratory Tract Infections in the Age of Resistance. <i>Pharmacotherapy</i> , 2002, 22, 1S-1S.	2.6	1
371	Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin-Tazobactam. <i>Pharmacotherapy</i> , 2002, 22, 569-577.	2.6	37
372	Antibacterials for the Prophylaxis and Treatment of Bacterial Endocarditis in Children. <i>Paediatric Drugs</i> , 2001, 3, 703-718.	3.1	6
373	Pharmacodynamic Assessment of Cefprozil against <i>Streptococcus pneumoniae</i> : Implications for Breakpoint Determinations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1291-1295.	3.2	41
374	Population Pharmacokinetics of Continuous Infusion Ceftazidime. <i>Clinical Pharmacokinetics</i> , 1999, 37, 343-350.	3.5	17
375	Pharmacokinetics and Pharmacodynamics of Continuous and Intermittent Ceftazidime during the Treatment of Nosocomial Pneumonia. <i>Clinical Drug Investigation</i> , 1999, 18, 133-139.	2.2	22
376	Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. <i>Journal of Orthopaedic Research</i> , 1998, 16, 76-79.	2.3	36
377	Infusion Phlebitis. <i>Clinical Drug Investigation</i> , 1998, 15, 531-535.	2.2	2
378	Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1614-1618.	1.0	25

#	ARTICLE	IF	CITATIONS
379	Pharmacoeconomics of <i>Pneumocystis carinii</i> Pneumonia in HIV-Infected and HIV-Noninfected Patients. <i>Pharmacoeconomics</i> , 1996, 10, 72-78.	3.3	6
380	Activities of Clarithromycin, Azithromycin, and Ofloxacin in Combination with Liposomal or Unencapsulated Granulocyte-Macrophage Colony-Stimulating Factor against Intramacrophage <i>Mycobacterium avium-Mycobacterium intracellulare</i> . <i>Journal of Infectious Diseases</i> , 1995, 172, 810-816.	4.0	36
381	In vitro elution of ofloxacin from a bioabsorbable polymer. <i>Acta Orthopaedica</i> , 1995, 66, 365-368.	1.4	34
382	Clinical Pharmacokinetics of Newer Cephalosporins. <i>Clinical Pharmacokinetics</i> , 1995, 28, 361-384.	3.5	40
383	The Effect of Fleroxacin and Ciprofloxacin on the Pharmacokinetics of Multiple Dose Caffeine. <i>Drugs</i> , 1995, 49, 357-359.	10.9	6
384	Intracellular and Extracellular Penetration of Azithromycin into Inflammatory and Noninflammatory Blister Fluid. <i>Antimicrobial Agents and Chemotherapy</i> , 1995, 39, 795-795.	3.2	0
385	Serum bactericidal activity of ceftriaxone plus metronidazole against common intra-abdominal pathogens. <i>American Journal of Health-System Pharmacy</i> , 1994, 51, 1782-1787.	1.0	0
386	Choosing between the New Cephalosporin Antibiotics. <i>Pharmacoeconomics</i> , 1994, 5, 34-39.	3.3	13
387	Lomefloxacin Clinical Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1993, 25, 6-19.	3.5	15